Treatment efficacy of the lead RNAIII-inhibiting peptide YSPWTNF-NH2 in acquired Staphylococcus aureus sepsis: a histopathological assessment.
The quorum-sensing interfering RNAIII-inhibiting peptide (RIP) YSPXTNF and its synthetic analogues YSPWTNF and YSPITNF have been shown to prevent and suppress diseases caused by Staphylococcus aureus at different body sites in different animal models. This study was designed to investigate histopathologically the therapeutic efficacy of lead peptide RIP YSPWTNF-NH(2) in the subcutaneous air sac murine model of acquired S. aureus sepsis. Two experimental protocols were evaluated: an infection/therapy protocol, for which twenty BALB/c mice per group were infected with a subcutaneous inoculum of S. aureus strain ATCC 25923 ( [Formula: see text] colony forming units) that were either pretreated or not with 150microg of peptide RIP, and a safety protocol, for which three uninfected mice per group received treatment with either 150microg of peptide RIP or saline. Therapeutic efficacy was assessed by clinical examination for a period of 20 days and histopathology at 12, 24, 36, 48, 96 and 168h after inoculation. Treatment safety was assessed histopathologically at 24, 48 and 264h after inoculation. Subcutaneous administration of uninfected control mice with a single dose of peptide RIP YSPWTNF caused no significant histopathology in most organs examined, except for slight to moderate lung and liver congestions. In contrast to the situation with the untreated infected control group mice that presented with histopathological alterations consistent with the diagnosis of rapidly progressive and highly erosive disease (100% mortality by day 3), treatment of infected animals with peptide RIP YSPWTNF had a profound therapeutic effect on survival rate (67% by day 20) and on disease progression. The histopathological examination confirmed the clinical findings showing that extensive tissue damage at the site of the infection and in organs were greatly suppressed in the peptide RIP-treated animals.
Ribeiro
Patrícia Damasceno
PD
Laboratório de Biotecnologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Avenida Alberto Lamego 2000, Parque Califórnia, Campos dos Goytacazes, RJ, CEP 28013-602, Brazil. enrique@medina-acosta.com
Ribeiro
Osmar Damasceno
OD
Marcolan
Ana Maria
AM
Medina-Acosta
Enrique
E
D000818:Animals; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D016372:RNA, Antisense / Q000037:antagonists & inhibitors*; D012329:RNA, Bacterial / Q000037:antagonists & inhibitors*; D018805:Sepsis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology; D015996:Survival Rate
D009842:Oligopeptides; D016372:RNA, Antisense; D012329:RNA, Bacterial; C111711:RNAIII inhibiting peptide; C096035:RNAIII, Staphylococcus aureus